An anonymous reader quotes a report from The Guardian: Hospitals -- despite being places where people implicitly expect to have their personal details kept private -- frequently use tracking technologies on their websites to share user information with Google, Meta, data brokers, and other third parties, according to research published today. Academics at the University of Pennsylvania analyzed a nationally representative sample of 100 non-federal acute care hospitals -- essentially traditional hospitals with emergency departments -- and their findings were that 96 percent of their websites transmitted user data to third parties. Additionally, not all of these websites even had a privacy policy. And of the 71 percent that did, 56 percent disclosed specific third-party companies that could receive user information.

The researchers' latest work builds on a study they published a year ago of 3,747 US non-federal hospital websites. That found 98.6 percent tracked and transferred visitors' data to large tech and social media companies, advertising firms, and data brokers. To find the trackers on websites, the team checked out each hospitals' homepage on January 26 using webXray, an open source tool that detects third-party HTTP requests and matches them to the organizations receiving the data. They also recorded the number of third-party cookies per page. One name in particular stood out, in terms of who was receiving website visitors' information. "In every study we've done, in any part of the health system, Google, whose parent company is Alphabet, is on nearly every page, including hospitals," [Dr Ari Friedman, an assistant professor of emergency medicine at the University of Pennsylvania] observed. "From there, it declines," he continued. "Meta was on a little over half of hospital webpages, and the Meta Pixel is notable because it seems to be one of the grabbier entities out there in terms of tracking."

Both Meta and Google's tracking technologies have been the subject of criminal complaints and lawsuits over the years -- as have some healthcare companies that shared data with these and other advertisers. In addition, between 20 and 30 percent of the hospitals share data with Adobe, Friedman noted. "Everybody knows Adobe for PDFs. My understanding is they also have a tracking division within their ad division." Others include telecom and digital marketing companies like The Trade Desk and Verizon, plus tech giants Oracle, Microsoft, and Amazon, according to Friedman. Then there's also analytics firms including Hotjar and data brokers such as Acxiom. "And two thirds of hospital websites had some kind of data transfer to a third-party domain that we couldn't even identify," he added. Of the 71 hospital website privacy policies that the team found, 69 addressed the types of user information that was collected. The most common were IP addresses (80 percent), web browser name and version (75 percent), pages visited on the website (73 percent), and the website from which the user arrived (73 percent). Only 56 percent of these policies identified the third-party companies receiving user information. In lieu of any federal data privacy law in the U.S., Friedman recommends users protect their personal information via the browser-based tools Ghostery and Privacy Badger, which identify and block transfers to third-party domains.

A brain implant startup called Synchron is preparing to recruit patients for a large-scale clinical trial to seek commercial approval for its device. Reuters reports: Synchron on Monday plans to launch an online registry for patients interested in joining the trial meant to include dozens of participants, and has received interest from about 120 clinical trial centers to help run the study, CEO Thomas Oxley said in an interview. "Part of this registry is to start to enable local physicians to speak to patients with motor impairment," he said. "There's a lot of interest so we don't want it to come in a big bottleneck right before the study we'll be doing."

Synchron received U.S. authorization for preliminary testing in July 2021 and has implanted its device in six patients. Prior testing in four patients in Australia showed no serious adverse side effects, the company has reported. Synchron will be analyzing the U.S. data to prepare for the larger study, while awaiting authorization from the U.S. Food and Drug Administration to proceed, Oxley said. Synchron and the FDA declined to comment on the expected timing of that decision. The company aims to include patients who are paralyzed due to the neurodegenerative disease ALS (amyotrophic lateral sclerosis), stroke and multiple sclerosis, Oxley said. [...]

Synchron's device is delivered to the brain via the large vein that sits next to the motor cortex in the brain instead of being surgically implanted into the brain cortex like Neuralink's. The FDA has asked Synchron to screen stroke patients using a non-invasive test to determine whether they would respond to an implant, Oxley said. "They want to expand the market to people who have had a stroke severe enough to cause paralysis because if limited to quadriplegia, the market is way too small to be sustainable," Kip Ludwig, former program director for neural engineering at the U.S. National Institutes of Health, said of Synchron. In 2020, Synchron reported that patients, opens new tab in its Australian study could use its first-generation device to type an average of 16 characters per minute. That's better than non-invasive devices that sit atop the head and record the electrical activity of the brain, which have helped people type up to eight characters per minute, but not the leap forward that is hoped for with an implant, Ludwig said. Oxley would not say whether typing has gotten faster or offer any other details from the ongoing U.S. trial. Reuters notes that Synchron's investors include billionaires Jeff Bezos and Bill Gates. It's competing with Elon Musk's Neuralink brain implant startup and claims it's farther along in the process of testing its device.

Earlier this year, Neuralink said it implanted a chip in its first human patient. It later said the patient fully recovered and was able to control a computer mouse using their thoughts.

"Varda Space Industries has closed a massive tranche of funding," reports TechCrunch, "just weeks after its first drug manufacturing capsule returned from orbit."

Varda has now raised $145 million to date, the article points out, and the $90 million in new Series B funding "marks an inflection point for the company, which is now gearing up to scale from the initial demonstration mission to a regular set of missions carrying customer payloads, Varda founder Delian Asparouhov told TechCrunch." El Segundo-based Varda was founded in 2021 by Asparouhov, who is also a partner at Founders Fund, and Will Bruey, a spacecraft engineer who cut his teeth at SpaceX. The pair had an audacious goal to commercialize what until very recently was promising but ultimately small-scale research into the effects of microgravity on pharmaceutical crystals... Astronauts have been conducting protein crystallization experiments in space for decades on the International Space Station and before that, the Space Shuttle. But the business case for expanding this research has never materialized — until now...

Part of the reason Varda is possible today is due to the availability of regular, low-cost rideshare launches from SpaceX and Rocket Lab's innovations in satellite bus manufacturing. Even beyond these external partnerships, the startup has made significant headway in its own right, as the success of the first mission showed: Their reentry capsule appears to have performed flawlessly and the experiment to reformulate the HIV medicine ritonavir was executed without a hitch, it says. Varda has also started publishing the results of its internal R&D efforts, including a scientific paper on its hyper-gravity (as opposed to microgravity) crystallization platform, which the startup developed as a sort of screening method prior to sending drugs to space. [The paper is titled "Gravity as a Knob for Tuning Particle Size Distributions of Small Molecules."] It's an entirely new field of research that takes advantage of the ability to truly unlock gravity as a variable in scientific experiments. "Over time, we will be able to generate data sets between both hyper-gravity and microgravity and start to show correlations," he said....

In a recent podcast appearance, he specified that the all-in initial mission cost around $12 million, which will drop to $5-6 million by mission 4 and $2.5 million or less by mission 10.) Larger capsules are also in the longer-term pipeline, though also not until the 2027 time frame. Asparouhov also confirmed that pharmaceuticals will be Varda's sole focus for the next 10-20 (or more) years, based on the company's conviction that pharmaceutical products will generate more economic value compared to other materials. A lot of that comes down to the fact that there are a significant set of drugs that require only a "seed" of the material that can only be made in microgravity, and the rest of the drug formulation can be completed here on Earth...

The company is also aiming to improve the processing capabilities of the on-board pharmaceutical reactor. The first mission carried just one drug protein, but in the future the company hopes to process multiple drug products that could be run through different processing regimes. In the future, other missions could carry larger reactors for drugs that do need more than the "seed" crystal, and those mission profiles would be closer to something like mass manufacturing.
Varda already has "a handful" of signed contracts with biotech companies, according to the article — and Varda's next manufacturing mission "will launch later this year."

SonicSpike shares a report from Scientific American: A day after the American Astronomical Society (AAS) announced that there were no signs of unsafe eclipse glasses or other solar viewers on the market in early March, astronomer and science communicator Rick Fienberg received an alarming call. Fienberg is project manager of the AAS Solar Eclipse Task Force, which is busy preparing for the total eclipse over North America on April 8. He's the creator of a list of vetted solar filters and viewers that will protect wearers' eyes as they watch the moon move in front of the sun. When a solar eclipse last crossed a major swath of the U.S. in 2017, Fienberg and his team spotted some counterfeit glasses entering the marketplace -- imitations that distributors claimed were manufactured by vetted companies. Testing at accredited labs indicated that many counterfeits were actually safe to use, however. This led the task force to describe such eclipse glasses as "misleading" but not "dangerous" in a March 11 statement meant to reassure the public.

But then Fienberg's phone rang. The caller was "a guy who had bought thousands of eclipse glasses from a distributor who had been on our list at one point," Fienberg says. "Those glasses were not safe. They were no darker than ordinary sunglasses." Legitimate eclipse glasses are at least 1,000 times darker than the darkest sunglasses you can buy. Fienberg contacted Cangnan County Qiwei Craft, a Chinese factory that he knew manufactured safe glasses and had -- in the past -- sold them to the distributor in question. But this time, Fienberg says, factory representatives told him they hadn't sold to that distributor in a long while. "That's when we switched from being concerned about only counterfeits to being concerned about actual fakes," Fienberg says. The AAS does not have a confident estimate of how many fake or counterfeit glasses are for sale out there. And though Fienberg doesn't think this is a widespread problem, the situation is an "iceberg kind of concern," he says, because there are likely more examples than the ones he knows about. While counterfeit glasses may still be safe to use, completely fake glasses could put wearers in serious danger. [...]

While lab tests are the best way to determine whether glasses meet the ISO standard, Fienberg says there is a three-part test people can do at home if they're concerned their eclipse viewers aren't up to the task. First, put your glasses on indoors and look around. The only things you should be able to see are very bright lights, such as a halogen bulb or a smartphone flashlight. Then, if the glasses pass the indoor test, bring them outside -- but don't look at the sun just yet. Look around: it should be too dark to see distant hills, trees or even the ground. If that second test is passed, keep the glasses on and quickly glance at the sun. You should comfortably see a bright, sharp-edged round disk. If your glasses pass all three tests, they are probably safe to wear. Still, Fienberg points out that it's best to use them for only a few seconds every minute or so during the eclipse; this cautious approach is how they're intended to be used. And if you don't trust your glasses for April's celestial event, you could try to find a reliable pair in the next two decades. "You only have to wait 20 years for another really good eclipse year in the [United] States," Fienberg says.

As a department of America's federal Health agency, the Food and Drug Administration is responsible for public health rules, including prescription medicines. And the FDA "has not changed its position that currently available clinical trial data do not demonstrate that ivermectin is effective against COVID-19," they confirmed to CNN this week. "The agency has not authorized or approved ivermectin for use in preventing or treating COVID-19."

But there was also a lawsuit. In "one of its more popular pandemic-era social media campaigns," the agency tweeted out "You are not a horse. You are not a cow. Seriously, y'all. Stop it." The post attracted nearly 106,000 likes — and over 46,000 reposts, and was followed by another post on Instagram. "Stop it with the #ivermectin. It's not authorized for treating #COVID."

Los Angeles Times business columnist Michael Hiltzik writes that the posts triggered a "groundless" lawsuit: It was those latter two lines that exercised three physicians who had been prescribing ivermectin for patients. They sued the FDA in 2022, asserting that its advisory illegally interfered with the practice of medicine — specifically with their ability to continue prescribing the drug. A federal judge in Texas threw out their case, but the 5th Circuit Court of Appeals — the source of a series of chuckleheaded antigovernment rulings in recent years — reinstated it last year, returning it to the original judge for reconsideration.

Now the FDA has settled the case by agreeing to delete the horse post and two similar posts from its accounts on the social media platforms X, LinkedIn and Facebook. The agency also agreed to retire a consumer advisory titled "Why You Should Not Use Ivermectin to Treat or Prevent COVID-19." In defending its decision, the FDA said it "has chosen to resolve this lawsuit rather than continuing to litigate over statements that are between two and nearly four years old."

That sounds reasonable enough, but it's a major blunder. It leaves on the books the 5th Circuit's adverse ruling, in which a panel of three judges found that the FDA's advisory crossed the line from informing consumers, which they said is all right, to recommending that consumers take some action, which they said is not all right... That's a misinterpretation of the law and the FDA's actions, according to Dorit Rubinstein Reiss of UC College of the Law in San Francisco. "The FDA will seek to make recommendations against the misuse of products in the future, and having that decision on the books will be used to litigate against it," she observed after the settlement.
"A survey by Boston University and the University of Michigan estimated that Medicare and private insurers had wasted $130 million on ivermectin prescriptions for COVID in 2021 alone."

When a long-term memory forms, some brain cells experience a rush of electrical activity so strong that it snaps their DNA. Then, an inflammatory response kicks in, repairing this damage and helping to cement the memory, a study in mice shows. Nature: The findings, published on 27 March in Nature, are "extremely exciting," says Li-Huei Tsai, a neurobiologist at the Massachusetts Institute of Technology in Cambridge who was not involved in the work. They contribute to the picture that forming memories is a "risky business," she says. Normally, breaks in both strands of the double helix DNA molecule are associated with diseases including cancer. But in this case, the DNA damage-and-repair cycle offers one explanation for how memories might form and last.

It also suggests a tantalizing possibility: this cycle might be faulty in people with neurodegenerative diseases such as Alzheimer's, causing a build-up of errors in a neuron's DNA, says study co-author Jelena Radulovic, a neuroscientist at the Albert Einstein College of Medicine in New York City. [...] To better understand the part these DNA breaks play in memory formation, Radulovic and her colleagues trained mice to associate a small electrical shock with a new environment, so that when the animals were once again put into that environment, they would 'remember' the experience and show signs of fear, such as freezing in place. Then the researchers examined gene activity in neurons in a brain area key to memory -- the hippocampus. They found that some genes responsible for inflammation were active in a set of neurons four days after training. Three weeks after training, the same genes were much less active.

Slashdot reader sciencehabit shared this report from Science magazine: Nurturing a growing fetus requires a series of profound physical, hormonal, and chemical changes that may rewire every major organ in the body and can cause serious health complications such as hypertension and preeclampsia. But does being pregnant actually take years off your life...?

Today in Cell Metabolism, scientists report that the stress of pregnancy can cause a person's biological age to increase by up to 2 years — a trend that may reverse itself in the months that follow. In some cases, the authors write, those who breastfeed their children after giving birth may end up biologically "younger" than during early pregnancy. The finding represents yet another piece of "compelling" evidence that events during and after pregnancy can have far-reaching health consequences, says Elizabeth Bertone-Johnson, an epidemiologist at the University of Massachusetts Amherst who wasn't involved in the new study...

The discovery that biological aging isn't necessarily a linear process "came as a real surprise," says Kieran O'Donnell, a perinatal researcher at the Yale School of Medicine... But blood samples from 68 participants, collected 3 months after giving birth, revealed a dramatic about-face. Although being pregnant had initially aged their cells between 1 and 2 years, says O'Donnell, their biological age now appeared to be 3 to 8 years younger than it had been during early pregnancy — with different epigenetic clocks algorithms providing slightly bigger or smaller estimates.

An AI tool named Mia, tested by the NHS, successfully detected signs of breast cancer in 11 women which had been missed by human doctors. The BBC reports: The tool, called Mia, was piloted alongside NHS clinicians and analyzed the mammograms of over 10,000 women. Most of them were cancer-free, but it successfully flagged all of those with symptoms, as well as an extra 11 the doctors did not identify. At their earliest stages, cancers can be extremely small and hard to spot. The BBC saw Mia in action at NHS Grampian, where we were shown tumors that were practically invisible to the human eye. But, depending on their type, they can grow and spread rapidly.

Barbara was one of the 11 patients whose cancer was flagged by Mia but had not been spotted on her scan when it was studied by the hospital radiologists. Because her 6mm tumor was caught so early she had an operation but only needed five days of radiotherapy. Breast cancer patients with tumors which are smaller than 15mm when discovered have a 90% survival rate over the following five years. Barbara said she was pleased the treatment was much less invasive than that of her sister and mother, who had previously also battled the disease. Without the AI tool's assistance, Barbara's cancer would potentially not have been spotted until her next routine mammogram three years later. She had not experienced any noticeable symptoms. "These results are encouraging and help to highlight the exciting potential AI presents for diagnostics. There is no question that real-life clinical radiologists are essential and irreplaceable, but a clinical radiologist using insights from validated AI tools will increasingly be a formidable force in patient care." said Dr Katharine Halliday, President of the Royal College of Radiologists.

An anonymous reader shares a report: Thanks to the vaccination program that began in 1995, chickenpox is now relatively rare. Cases of the miserable, itchy condition have fallen more than 97 percent. But, while children have largely put the oatmeal baths and oven mitts behind them, doctors have apparently let their diagnostic skills get a little crusty. According to a study published Thursday, public health researchers in Minnesota found that 55 percent of people diagnosed with chickenpox based on their symptoms were actually negative for the varicella-zoster virus, the virus that causes chickenpox. The study noted that the people were all diagnosed in person by health care providers in medical facilities. But, instead of chickenpox, lab testing showed that some of the patients were actually infected with an enterovirus, which can cause a rash, or the herpes simplex virus 1, which causes cold sores.

The study, published in the Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report, supports expanding laboratory testing for suspected chickenpox cases in the state's program and highlights that diagnoses based on symptoms are "unreliable." For one thing, doctors simply see far fewer chickenpox cases these days because of the protection from vaccines. While chickenpox cases in the US previously reached 4 million each year, with 10,500 to 13,500 hospitalizations and 100 to 150 deaths, there are now fewer than 150,000 cases,1,400 hospitalizations, and 30 deaths each year, the CDC reports. Vaccination is more than 90 percent effective at preventing the disease. In the rare cases where a vaccinated person contracts chickenpox, the muted rashes are challenging to identify by eye. But even in unvaccinated children, chickenpox can be tricky to pick out; it can easily be confused with measles, insect bites, enterovirus, skin infections such as scabies and impetigo, herpes viruses, and hand, foot, and mouth disease.

Neuralink, the brain-chip startup founded by Elon Musk, showed its first patient using his mind to play online chess. Reuters reports: Noland Arbaugh, the 29-year-old patient who was paralyzed below the shoulder after a diving accident, played chess on his laptop and moved the cursor using the Neuralink device. The implant seeks to enable people to control a computer cursor or keyboard using only their thoughts. Arbaugh had received an implant from the company in January and could control a computer mouse using his thoughts, Musk said last month.

"The surgery was super easy," Arbaugh said in the video streamed on Musk's social media platform X, referring to the implant procedure. "I literally was released from the hospital a day later. I have no cognitive impairments. I had basically given up playing that game," Arbaugh said, referring to the game Civilization VI, "you all (Neuralink) gave me the ability to do that again and played for 8 hours straight."

Elaborating on his experience with the new technology, Arbaugh said that it is "not perfect" and they "have run into some issues." "I don't want people to think that this is the end of the journey, there's still a lot of work to be done, but it has already changed my life," he added.

An anonymous reader quotes a report from Ars Technica: Google closed its Fitbit acquisition in 2021. Since then, the tech behemoth has pushed numerous changes to the wearable brand, including upcoming updates announced this week. While Google reshapes its fitness tracker business, though, some long-time users are regretting their Fitbit purchases and questioning if Google's practices will force them to purchase their next fitness tracker elsewhere.

As is becoming common practice with consumer tech announcements of late, Google's latest announcements about Fitbit seemed to be trying to convince users of the wonders of generative AI and how that will change their gadgets for the better. In a blog post yesterday, Dr. Karen DeSalvo, Google's chief health officer, announced that Fitbit Premium subscribers would be able to test experimental AI features later this year (Google hasn't specified when). "You will be able to ask questions in a natural way and create charts just for you to help you understand your own data better. For example, you could dig deeper into how many active zone minutes... you get and the correlation with how restorative your sleep is," she wrote. DeSalvo's post included an example of a user asking a chatbot if there was a connection between their sleep and activity and said that the experimental AI features will only be available to "a limited number of Android users who are enrolled in the Fitbit Labs program in the Fitbit mobile app."

Fitbit is also working with the Google Research team and "health and wellness experts, doctors, and certified coaches" to develop a large language model (LLM) for upcoming Fitbit mobile app features that pull data from Fitbit and Pixel devices, DeSalvo said. In a blog post yesterday, Yossi Matias, VP of engineering and research at Google, said Google wants to use the LLM to add personalized coaching features, such as the ability to look for sleep irregularities and suggest actions "on how you might change the intensity of your workout." Google's Fitbit is building the LLM on Gemini models that are tweaked on de-identified data from unspecified "research case studies," Matias said, adding: "For example, we're testing performance using sleep medicine certification exam-like practice tests." Other recent changes to Fitbit include a name tweak from Fitbit by Google, to Google Fitbit, as spotted by 9to5Google this week. Charge 5 users are especially concerned after users noticed their devices suddenly stopped holding a charge after a December firmware update was pushed. The problem has persisted with Google offering no solution other than offer discounts or, if the device was within its warranty period, a replacement.

"This is called planned obsolescence. I'll be upgrading to a watch style tracker from a different company. I wish Fitbit hadn't sold out to Google," a forum user going by Sean77024 wrote on Fitbit's support forum yesterday. "Others, like 2MeFamilyFlyer, have also accused Fitbit of planning Charge 5 obsolescence," notes Ars. "2MeFamilyFlyer said they're seeking a Fitbit alternative."

Several readers shared the following report: Intermittent fasting, a diet pattern that involves alternating between periods of fasting and eating, can lower blood pressure and help some people lose weight, past research has indicated. But an analysis presented Monday at the American Heart Association's scientific sessions in Chicago challenges the notion that intermittent fasting is good for heart health. Instead, researchers from Shanghai Jiao Tong University School of Medicine in China found that people who restricted food consumption to less than eight hours per day had a 91% higher risk of dying from cardiovascular disease over a median period of eight years, relative to people who ate across 12 to 16 hours.

It's some of the first research investigating the association between time-restricted eating (a type of intermittent fasting) and the risk of death from cardiovascular disease. The analysis -- which has not yet been peer-reviewed or published in an academic journal -- is based on data from the Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey collected between 2003 and 2018. The researchers analyzed responses from around 20,000 adults who recorded what they ate for at least two days, then looked at who had died from cardiovascular disease after a median follow-up period of eight years. However, Victor Wenze Zhong, a co-author of the analysis, said it's too early to make specific recommendations about intermittent fasting based on his research alone.

An anonymous reader quotes a report from CBC News: An array of advanced tests found no brain injuries or degeneration among U.S. diplomats and other government employees who suffer mysterious health problems once dubbed "Havana syndrome," researchers reported Monday. The National Institutes of Health's (NIH) nearly five-year study offers no explanation for symptoms including headaches, balance problems and difficulties with thinking and sleep that were first reported in Cuba in 2016 and later by hundreds of American personnel in multiple countries. But it did contradict some earlier findings that raised the spectre of brain injuries in people experiencing what the State Department now calls "anomalous health incidents."

"These individuals have real symptoms and are going through a very tough time," said Dr. Leighton Chan, NIH's chief of rehabilitation medicine, who helped lead the research. "They can be quite profound, disabling and difficult to treat." Yet sophisticated MRI scans detected no significant differences in brain volume, structure or white matter -- signs of injury or degeneration -- when Havana syndrome patients were compared to healthy government workers with similar jobs, including some in the same embassy. Nor were there significant differences in cognitive and other tests, according to findings published in the Journal of the American Medical Association.

An anonymous reader quotes a report from the BBC: The polio survivor known as "the man in the iron lung" has died at the age of 78. Paul Alexander contracted polio in 1952 when he was six, leaving him paralyzed from the neck down. The disease left him unable to breathe independently, leading doctors to place him in the metal cylinder, where he would spend the rest of his life. He would go on to earn a law degree -- and practice law -- as well as publish a memoir. [...] In 1952, when he became ill, doctors in his hometown of Dallas operated on him, saving his life. But polio meant his body was no longer able to breathe on his own. The answer was to place him in a so-called iron lung — a metal cylinder enclosing his body up to his neck.

The lung, which he called his "old iron horse," allowed him to breathe. Bellows sucked air out of the cylinder, forcing his lungs to expand and take in air. When the air was let back in, the same process in reverse made his lungs deflate. After years, Alexander eventually learned to breathe by himself so that he was able to leave the lung for short periods of time. Like most polio survivors placed in iron lungs, he was not expected to survive long. But he lived for decades, long after the invention of the polio vaccine in the 1950s all but eradicated the disease in the Western world. [...] Advances in medicine made iron lungs obsolete by the 1960s, replaced by ventilators. But Alexander kept living in the cylinder because, he said, he was used to it. He was recognized by Guinness World Records as the person who lived the longest in an iron lung.

Rates of more than a dozen cancers are increasing among adults under 50 worldwide, with the number of early-onset cancer cases predicted to rise by around 30% between 2019 and 2030. Investigators are searching for explanations, considering factors such as obesity, early-cancer screening, gut microbiome, and tumor genomes. Despite increased screening and awareness, mortality from early-onset cancers has risen by nearly 28% between 1990 and 2019 globally.

Surgeons in the United Kingdom have performed the first operation in the country using Apple's Vision Pro headset. TechSpot reports: During a recent operation to repair a patient's spine at the private Cromwell Hospital in London, a scrub nurse working alongside the surgeon used the Vision Pro to help prepare, keep track of the procedure, and choose the right tools, reports the Daily Mail. This marked the first operation in the UK where the Vision Pro was used. The software running on Apple's headset during the operation comes from US company eXeX, which has made similar programs for Microsoft's HoloLens. It offers nurses and technicians both holographic and touch-free access to the surgical setup and the procedural guides from within the sterile field of the operating room, according to the press release. The software also tracks each stage of an operation and can measure how well the op went compared to previous procedures performed by other surgeons.

"It eliminates human error and eliminates the guesswork," said Suvi Verho, lead scrub nurse at London Independent Hospital. "It gives you confidence in surgery." While this marked the first time that the Vision Pro was used during a UK surgery, the first-ever time the device was used in an operating room was last month, just three days after its release, when Orlando resident and world-renowned Neurosurgeon Dr. Robert Masson wore it during several spine reconstruction surgeries. "We are in a new era of surgery, and for the first time, our surgical teams have the brilliance of visual holographic guidance and maps, improving visuospatial and temporal orientation for each surgical team and for each surgery in all specialties," said Masson.

An anonymous Slashdot reader shared this article from Live Science: Manufacturers will no longer use harmful "forever chemicals" in food packaging products in the U.S., according to the U.S. Food and Drug Administration (FDA).

In a statement released February 28, the agency declared that grease-proofing materials that contain per- and polyfluoroalkyl substances (PFAS) will not be used in new food packaging sold in the U.S. These include PFAS used in fast-food wrappers, microwave popcorn bags, takeout boxes and pet food bags. The FDA's announcement marks the completion of a voluntary phase-out of the materials by U.S. food packaging manufacturers.

This action will eliminate the "major source of dietary exposure to PFAS," Jim Jones, deputy commissioner for human foods at the FDA, said in an associated statement. Companies told the FDA that it could take up to 18 months to completely exhaust the market supply of these products following their final date of sale. However, most of the affected manufacturers phased out the products faster than they initially predicted, the agency noted...

The FDA's new announcement marks a "huge win for the public," Graham Peaslee, a professor of physics at the University of Notre Dame who studies PFAS, told The Washington Post.

An anonymous reader quotes a report from The Guardian: Doctors have warned of potentially life-threatening effects from plastic pollution after finding a substantially raised risk of stroke, heart attack and earlier death in people whose blood vessels were contaminated with microscopic plastics. Researchers in Naples examined fatty plaques removed from the blood vessels of patients with arterial disease and found that more than half had deposits contaminated with tiny particles of polyethylene or polyvinyl chloride (PVC). Those whose plaques contained microplastics or nanoplastics were nearly five times more likely to suffer a stroke, heart attack or death from any cause over the following 34 months, compared with those whose plaques were free from plastic contamination. The findings do not prove that plastic particles drive strokes and heart attacks -- people who are more exposed to the pollution may be at greater risk for other reasons -- but research on animals and human cells suggests the particles may be to blame. [...]

Writing in the New England Journal of Medicine, the doctors describe how they analyzed fatty plaques removed from 304 patients with atherosclerosis affecting the carotid arteries. The carotid arteries are the main blood vessels that supply blood to the neck, face and brain. The disease causes a build-up of plaque in the arteries, which substantially raises the risk of stroke. The plaques can be removed by a procedure called carotid endarterectomy. Lab tests on the extracted plaques revealed polyethylene in 150 patients and polyvinyl chloride in 31, alongside signs of inflammation. On examination under an electron microscope, the researchers spotted jagged foreign particles in the fatty deposits, most less than a thousandth of a millimeter across. The doctors followed 257 of the patients for an average of 34 months after they had carotid plaques removed. Those who had plastic particles in their plaques were 4.5 times more likely to have a stroke or heart attack, or to die from any cause, than those whose plaques were free from plastic pollution. "People must become aware of the risks we are taking with our lifestyle," said Dr Raffaele Marfella, first author on the study at the University of Campania Luigi Vanvitelli in Naples. "I hope the alarm message from our study will raise the consciousness of citizens, especially governments, to finally become aware of the importance of the health of our planet. To put it in a slogan that can unite the need for health for humans and the planet, plastic-free is healthy for the heart and the Earth."

"A ransomware gang once thought to have been crippled by law enforcement has snarled prescription processing for millions of Americans over the past week..." reports the Washington Post.

"The hackers stole data about patients, encrypted company files and demanded money to unlock them, prompting the company to shut down most of its network as it worked to recover." Insurance giant UnitedHealthcare Group said the hackers struck its Change Health business unit, which routes prescription claims from pharmacies to companies that determine whether patients are covered by insurance and what they should pay... Change Health and a rival, CoverMyMeds, are the two biggest players in the so-called switch business, charging pharmacies a small fee for funneling claims to insurers. "When one of them goes down, obviously it's a major problem," said Patrick Berryman, a senior vice president at the National Community Pharmacists Association...

UnitedHealth estimated that more than 90 percent of the nation's 70,000-plus pharmacies have had to alter how they process electronic claims as a result of the Change Health outage. But it said only a small number of patients have been unable to get their prescriptions at some price. At CVS, which operates one of the largest pharmacy networks in the nation, a spokesperson said there are "a small number of cases in which our pharmacies are not able to process insurance claims" as a result of the outage. It said workarounds were allowing it to fill prescriptions, however...

For pharmacies that were not able to quickly route claims to a different company, the Change Health outage left pharmacists to try to manually calculate a patient's co-pay or offer them the cash price. Compounding the impact, thousands of organizations cut off Change Health from their systems to ensure the hackers did not infect their networks as well... The attack on Change Health has left many pharmacies in a cash-flow bind, as they face bills from the companies that deliver the medication without knowing when they will be reimbursed by insurers. Some pharmacies are requiring customers to pay full price for their prescriptions when they cannot tell if they are covered by insurance. In some cases, that means people are paying more than $1,000 out of pocket, according to social media posts.

The situation has been "extremely disruptive," said Erin Fox, associate chief pharmacy officer at University of Utah Health. "At our system, our retail pharmacies were providing three-day gratis emergency supplies for patients who could not afford to pay the cash price," Fox said by email. "In some cases, like for inhalers, we had to send product out at risk, not knowing if we will ever get paid, but we need to take care of the patients." Axis Pharmacy Northwest near Seattle is "going out on a limb and dispensing product with absolutely no inkling if we'll get paid or not," said Richard Molitor, the pharmacist in charge. UPDATE: CNN reports Change Healthcare has now announced "plans for a temporary loan program to get money flowing to health care providers affected by the outage." It's a stop-gap measure meant to give some financial relief to health care providers, which analysts say are losing millions of dollars per day because of the outage. Some US officials and health care executives told CNN it may be weeks before Change Healthcare returns to normal operations.
"Once standard payment operations resume, the funds will simply need to be repaid," the company said in a statement. Change Healthcare has been under pressure from senior US officials to get their systems back online. Officials from the White House and multiple federal agencies, including the department of Health and Human Services, have been concerned by the broad financial and health impact of the hack and have been pressing for ways to get Change Healthcare back online, sources told CNN...

In a message on its website Friday afternoon, Change Healthcare also said that it was launching a new version of its online prescribing service following the cyberattack.
Thanks to Slashdot reader CaptainDork for sharing the news.

An anonymous reader quotes a report from The Guardian: Microplastics have been found in every human placenta tested in a study, leaving the researchers worried about the potential health impacts on developing fetuses. The scientists analyzed 62 placental tissue samples and found the most common plastic detected was polyethylene, which is used to make plastic bags and bottles. A second study revealed microplastics in all 17 human arteries tested and suggested the particles may be linked to clogging of the blood vessels. [...] Prof Matthew Campen, at the University of New Mexico, US, who led the research, said: "If we are seeing effects on placentas, then all mammalian life on this planet could be impacted. That's not good." He said the growing concentration of microplastics in human tissue could explain puzzling increases in some health problems, including inflammatory bowel disease (IBD), colon cancer in people under 50, and declining sperm counts. A 2021 study found people with IBD had 50% more microplastics in their feces. Campen said he was deeply concerned by the growing global production of plastics because it meant the problem of microplastics in the environment "is only getting worse."

The research, published in the Toxicological Sciences journal, found microplastics in all the placenta samples tested, with concentrations ranging from 6.5 to 790 micrograms per gram of tissue. PVC and nylon were the most common plastics detected, after polyethylene. The microplastics were analyzed by using chemicals and a centrifuge to separate them from the tissue, then heating them and analyzing the characteristic chemical signature of each plastic. The same technique was used by scientists at the Capital Medical University in Beijing, China, to detect microplastics in human artery samples. The concentration of microplastics in placentas was especially troubling, Campen said. The tissue grows for only eight months, as it starts to form about a month into pregnancy. "Other organs of your body are accumulating over much longer periods of time," he added.